TBPH Stock TBPH is expected to report earnings to fall -47% to -25 cents per share on May 13

A.I.dvisor
at Tickeron.com
05/12/24
Loading...
TBPH - Theravance Biopharma
Theravance Biopharma Earnings Graph
Q1'24
Est.
$-0.25
Q4'23
Missed
by $0.02
Q3'23
Beat
by $0.04
Q2'23
Beat
by $1.19
Q1'23
Missed
by $0.09
The last earnings report on December 31 showed earnings per share of -17 cents, missing the estimate of -15 cents. P/B Ratio (2.139) is normal, around the industry mean (10.609). P/E Ratio (0.000) is within average values for comparable stocks, (160.883). TBPH's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (1.422). Dividend Yield (0.000) settles around the average of (0.066) among similar stocks. P/S Ratio (9.033) is also within normal values, averaging (236.959). With 339.09K shares outstanding, the current market capitalization sits at 455.49M.
View a ticker or compare two or three
TBPHDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of small molecule pharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
Ugland House, South Church Street
Phone
+1 650 808-6000
Employees
99
Web
https://www.theravance.com